Ben Kennedy

Leicester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine

Published: June 16, 2025

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Journal: The New England journal of medicine

Published: December 11, 2023

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: January 16, 2023

Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.

Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.

Journal: British journal of haematology

Published: December 21, 2022

Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial.

Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial.

Journal: British journal of haematology

Published: April 30, 2022

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroconversion in hematology-oncology patients.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroconversion in hematology-oncology patients.

Journal: Journal of medical virology

Published: September 26, 2020

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.

Journal: Haematologica

Published: February 13, 2020

Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis.

Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis.

Journal: British journal of haematology

Published: August 03, 2018

Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline.

Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline.

Journal: British journal of haematology

Published: July 17, 2018

CUDC-907 blocks multiple pro-survival signals and abrogates microenvironment protection in CLL.

CUDC-907 blocks multiple pro-survival signals and abrogates microenvironment protection in CLL.

Journal: Journal of cellular and molecular medicine

Published: July 03, 2018

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.

Journal: Haematologica

Published: February 06, 2018

A Double Hit CD10-Negative B-Cell Lymphoma with t(3;8)(q27;q24) Leading to Juxtaposition of the BCL6 and MYC Loci Associated with Good Clinical Outcome.

A Double Hit CD10-Negative B-Cell Lymphoma with t(3;8)(q27;q24) Leading to Juxtaposition of the BCL6 and MYC Loci Associated with Good Clinical Outcome.

Journal: Case reports in hematology

Published: August 08, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026